4SC
4SC AG is a German biopharmaceutical company that historically developed targeted small-molecule oncology drugs, principally Resminostat (Kinselby); as of late 2025 it has no products in development, no operational business, has delisted from the Frankfurt Stock Exchange, and exists as a dormant public shell with preserved tax loss carryforwards.
- Company typePublic
- Founded1997
- HeadquartersPlanegg, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What 4SC does
4SC AG is a German biopharmaceutical company (Aktiengesellschaft) headquartered at Fraunhoferstrasse 22, 82152 Planegg-Martinsried near Munich. Historically the company discovered and developed targeted small-molecule drugs for cancer and autoimmune diseases, with its principal asset Resminostat (marketed as Kinselby) an epigenetic (HDAC-inhibitor) compound intended for haematological and dermatological oncology indications. The firm operated a classic clinical-stage biotech model, generating revenue (where generated) through development milestones, licensing, and partnership arrangements rather than direct sales, with prior partnerships visible across its pipeline page and capital history.
As of the most recent disclosures, 4SC explicitly states on its own website that it 'has currently no products in development and no operational business' and that 'no clinical trials are being conducted'. The company therefore has no live products, no revenue-generating customers, and no active go-to-market motion; contact infrastructure remains in place primarily for residual pharmacovigilance obligations and investor/corporate communications. Ownership is concentrated under Athos KG, which indirectly holds 72.44% of voting rights.
In late 2025 the company executed a structural transaction: following an AGM resolution on 19 September 2025 and a binding tax ruling in November 2025 confirming preservation of tax loss carryforwards, 4SC completed a capital reduction to zero with simultaneous subscription-rights capital increase of approximately EUR 2.7 million on 16 December 2025. This expired all old shares (ISIN DE000A3E5C40) without compensation, removed the company from the Frankfurt Stock Exchange Prime Standard, and re-issued new shares (ISIN DE000A0L1LC2) that are not admitted to stock-exchange trading. The result is a delisted, dormant German public company shell whose principal asset is preserved tax losses and a clean post-restructuring capital structure.
4SC firmographics
Firmographics- Name
- 4SC
- Legal name
- 4SC AG
- Website
- https://4sc.de
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- 4SC AG is a German biopharmaceutical company that historically developed targeted small-molecule oncology drugs, principally Resminostat (Kinselby); as of late 2025 it has no products in development, no operational business, has delisted from the Frankfurt Stock Exchange, and exists as a dormant public shell with preserved tax loss carryforwards.
- Ownership category
- akta.pro rank
4SC industry classification
Industry- Product category
- Biopharmaceutical Oncology Drug Development
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where 4SC is headquartered
LocationHeadquarters
- HQ city
- Planegg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
4SC business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
4SC product offering
Product offeringCore offering
4SC AG historically discovered and developed targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases, with its lead asset being the out-licensed epigenetic oncology drug Resminostat (Kinselby). As stated by the company, 4SC currently has no products in development and no operational business, and is not conducting any clinical trials.
Product overview
4SC AG is a German biopharmaceutical company that, as of the source data, has no products in development and no operational business. The company underwent a capital reduction to zero with simultaneous capital increase and delisted from the Frankfurt Stock Exchange in December 2025. The company's sole focus had been on its biopharmaceutical product Resminostat (Kinselby).
Differentiator
Problem solved
Functional benefit
Products and services
- Resminostat (Kinselby) Resminostat (Kinselby) is 4SC AG's lead partnered/out-licensed small-molecule oncology drug candidate, historically positioned for epigenetic (HDAC-inhibitor) treatment of cancer indications. It is listed under 4SC's 'Verpartnerte Produkte' (partnered/out-licensed products) section of the product pipeline.
Companies that use 4SC
Customer profileIdeal customer profiles1 record
4SC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
4SC partnerships and signals
Strategic signalScale indicators2 records
Recent moves7 records
Expansion highlights3 records
4SC competitors and assessment
Company assessmentDirect peers
- Syndax Pharmaceuticals: US clinical-stage oncology company developing HDAC inhibitor entinostat, the most direct mechanistic peer to 4SC's Resminostat program. Comparable in epigenetic-modulator approach and oncology focus.
- Curis: Clinical-stage biotech focused on targeted oncology including epigenetic and small-molecule approaches. Directly comparable to 4SC's prior small-molecule oncology discovery model.
- MEI Pharma: Small-cap clinical oncology company with HDAC inhibitor (pracinostat) experience and similar pipeline-focused, partnership-driven business model to 4SC's historical operations.
Regional players
- Evotec SE: German biotech platform company providing drug discovery and development services. Comparable as a fellow Munich-area biotech with small-molecule expertise, though broader and operationally active unlike dormant 4SC.
- MorphoSys: German biotech (now part of Novartis) historically focused on hematology/oncology therapeutics. Comparable as a German small-cap oncology developer that underwent major corporate transformation.
- Heidelberg Pharma: German clinical-stage oncology company developing antibody-targeted therapeutics. Comparable as a small-cap German biotech with a similar operating scale and oncology focus.
- Medigene AG: German clinical-stage immuno-oncology company. Comparable as a small German biotech listed in Germany that has undergone restructuring and pipeline refocusing, similar in scale and stage.
Broad incumbents
- Otsuka Holdings: Japanese pharmaceutical group that previously held development and commercialization rights to Resminostat in Japan. Directly comparable as a former partner/competitor in the Resminostat franchise.
- Pierre Fabre: French pharmaceutical group active in oncology. Relevant as a potential commercialization partner for any relicensed 4SC oncology assets given the European oncology overlap.
Emerging players
- NewLink Genetics (LumiraDx-era assets): Clinical-stage oncology company that has undergone multiple transformations and restructurings. Comparable trajectory to 4SC's transition into a dormant or transformed entity.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights4 records
Customer concentration
4SC social profiles
Digital presence4SC financial estimates
Financial estimateRevenue estimate
Valuation estimate
4SC leadership team
Management profileNumber of profiles
Profiles6 records
4SC funding detail
Funding detailFunding overview
Funding rounds8 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
4SC M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 4SC
What does 4SC do?
4SC AG historically discovered and developed targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases, with its lead asset being the out-licensed epigenetic oncology drug Resminostat (Kinselby). As stated by the company, 4SC currently has no products in development and no operational business, and is not conducting any clinical trials.
Is 4SC a public or private company?
4SC is a public company. It is classified as private equity controlled and is currently operating.
When was 4SC founded?
4SC was founded in 1997. It employs 51 to 100 people.
Where is 4SC based?
4SC is headquartered in Planegg, Germany, in the Europe region.
Who are 4SC's main competitors?
Direct peers on record are Syndax Pharmaceuticals, Curis and MEI Pharma. Regional players are Evotec SE, MorphoSys, Heidelberg Pharma and Medigene AG. Broad incumbents are Otsuka Holdings and Pierre Fabre. NewLink Genetics (LumiraDx-era assets) is listed as an emerging player.
Does 4SC have an API?
No public API is recorded for 4SC.
What industry is 4SC in?
4SC's product category is Biopharmaceutical Oncology Drug Development. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 3254 and its SIC code is 2834.